Notably, IDH mutations, which are prevalent in 80% of the C5 subtype [20], are known to mitigate leukocyte chemotaxis, thereby reducing the presence of tumor‐associated immune cells and improving prognosis [21]. The gene discussed is IDH1; the disease is neoplasm.